Natural thyroid: new announcement, same old news

The FDA issued a new statement last week on unapproved animal-derived thyroid medications – desiccated thyroid extract, or DTE – signaling its intent to issue compliance guidance by August 2026 and making clear that DTE is not eligible for compounding. The agency’s reasoning: these products are biologics under the public Health Service Act, not drugs, which puts them outside traditional compounding pathways.

The announcement may be new, but it’s the same news.

APC’s Scott Brunner pushed back, and the core objection is hard to argue with. FDA’s own longstanding policy has been that inactive ingredients don’t determine whether a product is regulated as a biologic. Recasting DTE on that basis, after decades of treating it as a drug, isn’t a technical clarification. It’s a fundamental contradiction of the agency’s own framework, and one the agency hasn’t come close to adequately justifying.

The practical consequences are real. Patients across the country rely on prescriber-directed, compounding DTE formulations because commercially available alternatives have failed them or aren’t tolerable. What the FDA is proposing narrows both the commercial and compounding pathways simultaneously, while offering no immediate alternative for patients, leaving a very real hole in continuity of care.

While Brunner says APC supports rigorous standards and appropriate oversight, abrupt policy shifts that contradict prior agency positions and leave patients without options aren’t that.